支气管扩张与慢阻肺的关联:欧洲支气管扩张登记(EMBARC)数据
基于欧洲支气管扩张登记(EMBARC)28国16730例CT确诊支气管扩张患者的前瞻性观察分析,4336例被临床医生共同诊断为慢阻肺。研究发现慢阻肺存在明显过度诊断:22.2%无气流阻塞、31.9%无≥10包年吸烟史,仅2157例(55.4%)符合ROSE标准。符合ROSE标准者随访期急性加重及住院风险显著增加。
要点
- 支气管扩张患者中慢阻肺临床标签常见但过度诊断突出,仅55.4%符合ROSE客观标准。
- 符合ROSE标准者急性加重风险IRR 1.25(95%CI 1.15-1.35),住院急性加重IRR 1.69(95%CI 1.51-1.90)。
- 临床标签慢阻肺者急性加重更多、生活质量更差、严重度评分更高。
核心结论
- 支气管扩张患者中慢阻肺标签常被用于无客观气流阻塞或吸烟史者,临床标签慢阻肺者临床结局更差。
研究设计与样本
- EMBARC前瞻性观察研究,纳入28国16730例CT确诊支气管扩张患者,随访最长5年。
- 采用ROSE标准(影像学支气管扩张、FEV1/FVC<0.7、症状、≥10包年吸烟)客观定义支气管扩张与慢阻肺的关联。
主要发现
- 4336例有临床医生共同诊断的慢阻肺,这些患者急性加重更多、生活质量更差、严重度评分更高。
- 22.2%的慢阻肺诊断患者无气流阻塞,31.9%无≥10包年吸烟史。
- 2157例(55.4%)符合ROSE标准慢阻肺。
- 符合ROSE标准者随访期急性加重风险IRR 1.25(95%CI 1.15-1.35),住院急性加重IRR 1.69(95%CI 1.51-1.90)。
关键数值与推荐
- ROSE标准:影像学支气管扩张(R)、FEV1/FVC<0.7(O)、症状(S)、≥10包年吸烟(E)。
- 慢阻肺过度诊断:22.2%无气流阻塞,31.9%无≥10包年吸烟史。
- 仅55.4%(2157例)符合ROSE标准慢阻肺。
临床怎么用
- 对支气管扩张患者诊断慢阻肺应基于客观气流阻塞和吸烟暴露,避免仅凭临床标签。
- 符合ROSE标准者应加强急性加重和住院风险管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: COPD and bronchiectasis are commonly reported together. Studies report varying impacts of co-diagnosis on outcomes, which may be related to different definitions of disease used across studies. Objectives: To investigate the prevalence of chronic obstructive pulmonary disease (COPD) associated with bronchiectasis and its relationship with clinical outcomes. We further investigated the impact of implementing the standardized ROSE criteria (radiological bronchiectasis [R], obstruction [FEV1/FVC ratio <0.7; O], symptoms [S], and exposure [⩾10 pack-years of smoking; E]), an objective definition of the association of bronchiectasis with COPD. Methods: Analysis of the EMBARC (European Bronchiectasis Registry), a prospective observational study of patients with computed tomography-confirmed bronchiectasis from 28 countries. The ROSE criteria were used to objectively define the association of bronchiectasis with COPD. Key outcomes during a maximum of 5 years of follow-up were exacerbations, hospitalization, and mortality. Measurements and Main Results: A total of 16,730 patients with bronchiectasis were included; 4,336 had a clinician-assigned codiagnosis of COPD, and these patients had more exacerbations, worse quality of life, and higher severity scores. We observed marked overdiagnosis of COPD: 22.2% of patients with a diagnosis of COPD did not have airflow obstruction and 31.9% did not have a history of ⩾10 pack-years of smoking. Therefore, 2,157 patients (55.4%) met the ROSE criteria for COPD. Compared with patients without COPD, patients who met the ROSE criteria had increased risks of exacerbations and exacerbations resulting in hospitalization during follow-up (incidence rate ratio, 1.25; 95% confidence interval, 1.15-1.35; vs. incidence rate ratio, 1.69; 95% confidence interval, 1.51-1.90, respectively). Conclusions: The label of COPD is often applied to patients with bronchiectasis who do not have objective evidence of airflow obstruction or a smoking history. Patients with a clinical label of COPD have worse clinical outcomes.
引用
- Polverino E, De Soyza A, Dimakou K, et al. The Association between Bronchiectasis and Chronic Obstructive Pulmonary Disease: Data from the European Bronchiectasis Registry (EMBARC). Am J Respir Crit Care Med. 2024. PMID: 38271696. doi:10.1164/rccm.202309-1614OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。